Robert Brady Recognized by Food and Drug Law Institute for Distinguished Service and Leadership

WASHINGTON, D.C., 9 December 2011 – Hogan Lovells announced today that the Food and Drug Law Institute (FDLI) presented its 2011 Distinguished Service and Leadership award to Robert Brady, a partner in the firm’s Pharmaceutical and Biotechnology Practice Group.

Brady was one of four honorees from the FDA regulatory bar who were recognized for their service and leadership. He was cited for his accomplishments in a career that includes service in several positions at the Food and Drug Administration and more than fifteen years at Hogan Lovells. This award follows a number of other accolades Brady has received, including being named by Legal Times as one of the leading food and drug lawyers in Washington, D.C., and receiving a first-tier ranking from Chambers USA.

“I am personally honored to receive this award, recognizing that I’ve been fortunate to collaborate with superb colleagues at the FDA and at Hogan Lovells over the years,” said Brady.

Hogan Lovells’ Pharmaceutical and Biotechnology Practice Group was recognized in 2011 by Chambers USA as part of the top-ranked (Band 1) pharmaceutical/medical products regulatory practice in the District of Columbia. It is part of the firm’s Health Practice, which this year received a Chambers USA Award for Excellence and a first-tier ranking for healthcare in the U.S. edition of the Legal 500. In addition, a number of lawyers in the Pharmaceutical and Biotechnology Practice Group and the Health Practice were ranked by Chambers USA as leading practitioners in the nation.

“Bob Brady exemplifies why our regulatory practices are part of what distinguishes Hogan Lovells from its competitors,” said Partner Philip Katz, Practice Area Co-Leader of Hogan Lovells’ Pharmaceutical and Biotechnology Practice Group. “As the FDLI cited in giving this award, Bob focuses on knowing the law well, providing insight as to how the FDA operates, understanding the pharmaceutical industry, and working collaboratively with his colleagues. We are grateful for all he has done, and proud of his accomplishments.”

Share Back To Listing

Loading data